Avadel Pharmaceuticals Receives Acquisition Proposal from Lundbeck

Avadel Pharmaceuticals ( (AVDL) ) has issued an announcement.

On November 14, 2025, Avadel Pharmaceuticals announced receiving an unsolicited acquisition proposal from H. Lundbeck A/S, offering up to $23.00 per ordinary share, which includes cash and contingent value rights based on future sales milestones. The Avadel Board considers this proposal potentially superior to its existing agreement with Alkermes, which offers up to $20.00 per share. However, Avadel’s Board has not yet determined the Lundbeck proposal as superior and continues to support the Alkermes acquisition while engaging in discussions with Lundbeck.

The most recent analyst rating on (AVDL) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.

Spark’s Take on AVDL Stock

According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.

Avadel Pharmaceuticals is on a positive trajectory with strong revenue growth and cash flow improvements. The bullish technical indicators support a positive outlook, although the stock is currently overbought. The earnings call provided a boost with positive guidance and sentiment. However, ongoing profitability challenges and a negative P/E ratio weigh on the overall score.

To see Spark’s full report on AVDL stock, click here.

More about Avadel Pharmaceuticals

Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing innovative medications to address treatment challenges faced by patients. Its commercial product, LUMRYZ™, is approved by the FDA as the first once-at-bedtime oxybate for extended-release oral suspension, treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged 7 and older.

Average Trading Volume: 2,463,384

Technical Sentiment Signal: Buy

Current Market Cap: $1.87B

For detailed information about AVDL stock, go to TipRanks’ Stock Analysis page.